My bookmarksSign up free

Commission Delegated Regulation (EU) 2017/1569 Article 26

Commission Delegated Regulation (EU) 2017/1569 Article 26

Transitional provision

Article 26

The Member States may continue to apply national transposition measures adopted under Commission Directive 2003/94/EC  ( 5 ) to the manufacture of investigational medicinal products used in clinical trials governed by Directive 2001/20/EC of the European Parliament and of the Council  ( 6 ) in accordance with the transitional provisions laid down in Article 98 of Regulation (EU) No 536/2014.

Read the full instrument → · Read this in context: CHAPTER IV — FINAL PROVISIONS →

Other provisions in CHAPTER IV — FINAL PROVISIONS

Compiled from an official source version. Later amendments or repeals may not be reflected; the official text prevails. · Read the official text ↗ · Data as of 2026-07-04

CitationArticle 26 of Commission Delegated Regulation (EU) 2017/1569 (LawPlayer, data as of 2026-07-04)

© European Union, https://eur-lex.europa.eu, 1998-2026. Reuse authorised under Commission Decision 2011/833/EU, provided the source is acknowledged.

What to look at next

Commission Delegated Regulation (EU) 2017/1569, full textChapter navigation and full text, so you can read this section in contextEuropean Union legislationEU Legal Acts by type and yearGrouped by instrument type and year of enactment, so you can find others of the same kindBrowse by type and yearCHAPTER IV — FINAL PROVISIONS — read this in contextThe surrounding text of the act in order, so you can see what comes before and afterChapters and sections